Clinical Trial Update: Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease

View source ↗

Summary

The expanded access protocol for RAVICTI to treat Byler disease is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Byler Disease

Drugs mentioned

• Ravicti (glycerol phenylbutyrate)

Snippet

Sponsor: Robert Squires, Jr. | Conditions: Byler Disease | Status: NO_LONGER_AVAILABLE